Related by context. All words. (Click for frequent words.) 72 relapsing remitting MS RRMS 72 relapsed MM 71 COPAXONE R 71 PREZISTA r 70 relapsing remitting multiple sclerosis 69 riociguat 69 APTIVUS r 69 cediranib 69 oral FTY# 69 RoACTEMRA 69 heavily pretreated patients 68 weekly subcutaneous injections 68 pomalidomide 68 AGILECT R 68 recurrent glioblastoma multiforme 68 metastatic RCC 68 stage IIIB 68 dirucotide MBP# 68 Traficet EN 68 placebo controlled clinical trials 68 crizotinib PF # 68 adalimumab 67 DMARD therapy 67 sunitinib malate 67 forodesine 67 SCIg 67 vicriviroc 67 GAMMAGARD 67 heavily pretreated 67 teriflunomide 67 randomized multicenter trial 67 genotypic resistance 67 phase IIb trial 67 RSD# oral 67 tocilizumab 67 decitabine 67 glatiramer acetate 67 immunomodulatory therapy 67 placebo controlled clinical 67 ACZ# 67 MERLIN TIMI 67 receptor tyrosine kinase inhibitor 67 desvenlafaxine succinate 67 protease inhibitor PI 67 CIMZIA TM 66 Tolvaptan 66 refractory CLL 66 mRCC 66 low dose cytarabine 66 COPAXONE ® 66 placebo controlled trials 66 metastatic renal cell carcinoma 66 aripiprazole Abilify 66 relapsing multiple sclerosis 66 efalizumab 66 ACTEMRA TM 66 SJIA 66 bendamustine 66 phase Ib 66 axitinib 66 lamivudine refractory patients 66 laquinimod 66 mitoxantrone plus 66 ORENCIA ® 66 Teriflunomide 66 oral rivaroxaban 66 regorafenib 66 MIRAPEX 66 ancrod 66 virological failure 66 CAMMS# 66 leukemia AML 66 virological response 66 acromegalic patients 66 PEGylated interferon beta 1a 66 dose escalation phase 66 PreCISe study 66 Ophena TM 66 adult chronic ITP 66 lupus nephritis 66 interferon beta therapy 65 dose cohort 65 relapsing MS 65 antiretroviral naive 65 SNT MC# 65 canakinumab 65 Natalizumab 65 venlafaxine XR 65 ABSORB trial 65 mCRC patients 65 pramipexole 65 evaluable subjects 65 YONDELIS 65 Betaferon ® 65 trastuzumab Herceptin ® 65 vandetanib 65 Phase #/#a 65 HCV SPRINT 65 ZACTIMA 65 somatostatin analog 65 dosing cohort 65 dose cohorts 65 plus methotrexate 65 TNF antagonist 65 Phase IIIb clinical 65 recurrent GBM 65 MAGE A3 ASCI 65 blinded randomized placebo controlled 65 temsirolimus 65 visilizumab 65 galiximab 65 EVIZON 65 phase IIa 65 Amrubicin 65 CANCIDAS 65 IFN beta 65 divalproex sodium 65 refractory CTCL 65 elotuzumab 65 alemtuzumab treated 65 nitazoxanide 65 APTIVUS 65 Certolizumab pegol 65 CYT# potent vascular disrupting 65 SUTENT 65 HBeAg negative 65 cilengitide 65 RLAI 65 VELCADE melphalan 65 HBeAg positive patients 65 Betaferon R 65 rFVIIa 65 atazanavir ritonavir 65 Tasimelteon 65 paricalcitol 65 TNF inhibitor 65 phase IIb study 65 CIMZIA TM certolizumab pegol 65 cisplatin chemotherapy 64 active comparator 64 oral methylnaltrexone 64 LEXIVA r 64 RESIST studies 64 MGd 64 posaconazole 64 methotrexate therapy 64 viral kinetics 64 vidofludimus 64 MIRCERA 64 APTIVUS R 64 Phase IIIb study 64 dosage regimens 64 CCR5 antagonist 64 HuMax EGFr 64 REMICADE ® 64 CYPHER R Sirolimus eluting 64 HBeAg positive 64 BARACLUDE ® 64 ritonavir boosted 64 dosing cohorts 64 PRECiSE 64 AIR CF1 64 antiepileptic drug 64 CIMZIA ™ 64 virologic failure 64 Temsirolimus 64 HGS# 64 NATRECOR ® 64 Phase III placebo controlled 64 BRIM2 64 lumiliximab 64 GSK# [001] 64 cinacalcet 64 methotrexate monotherapy 64 TYKERB 64 EDSS scores 64 dirucotide 64 interferon beta 1b 64 #mg BID [001] 64 phase IIb clinical 64 fluvastatin 64 multicenter Phase III 64 antiarrhythmic drugs 64 randomized #:#:# 64 MACUGEN 64 Dasatinib 64 recurrent glioblastoma 64 tasocitinib 64 romiplostim 64 dexmedetomidine 64 phase IIa clinical 64 bosentan 64 placebo controlled Phase III 64 AVERROES 64 refractory acute myeloid 64 antiangiogenic therapy 64 rilonacept 64 Afatinib 64 prucalopride 64 chlorambucil 64 placebo controlled studies 64 docetaxel chemotherapy 64 virologic breakthrough 64 Arranon 64 Alemtuzumab 64 Roche Xeloda 64 multicenter randomized placebo controlled 64 MabCampath 64 KRAS mutations occur 64 adalimumab Humira 64 Plicera 64 remission induction 64 PROCHYMAL 64 Rebif ® 64 intravenous cyclophosphamide 63 apremilast 63 intermittent dosing 63 phase IIIb 63 Raptiva ® 63 randomized multicenter 63 Torisel 63 β blockers 63 symptomatic BPH 63 TORISEL 63 certolizumab 63 evaluable patients 63 DAPT 63 Phase 2a trial 63 adjuvant tamoxifen 63 Phase Ib study 63 refractory metastatic 63 elacytarabine 63 cannabinor 63 non squamous NSCLC 63 BoNTA 63 Seliciclib 63 Doxil ® 63 biologic DMARD 63 mycophenolate mofetil 63 BAY #-# 63 histologically confirmed 63 cholinesterase inhibitor 63 PROMACTA 63 dose escalation Phase 63 alvespimycin 63 TDF FTC 63 INVEGA ® 63 ximelagatran 63 natalizumab 63 amrubicin 63 pyridostigmine 63 dose escalation clinical 63 CRVO 63 tipranavir r 63 anterior uveitis 63 etanercept 63 lenalidomide dexamethasone 63 lapatinib Tykerb 63 trials RCTs 63 TACI Ig 63 octreotide LAR 63 HuMax CD4 63 Cloretazine 63 dose regimens 63 mg kg dose 63 OHR/AVR# 63 MYCAMINE 63 sorafenib tablets 63 SYN# 63 Tarceva TM 63 NRTI 63 Pemetrexed 63 autoantibody positive 63 NLX P# 63 icatibant 63 EGFR TKI 63 sitaxsentan 63 intravenous dosing 63 APTIVUS ritonavir 63 pegaptanib 63 viral kinetic 63 KRAS status 63 phase IIb 63 Tamibarotene 63 fostamatinib 63 IV NSCLC 63 timepoints 63 treatment naïve genotype 63 randomized blinded 63 abiraterone acetate 63 Safinamide 63 uric acid lowering 63 placebo controlled Phase 63 trabectedin 63 #mg/day [001] 63 CLARITY study 63 Pivotal Phase III 63 Cimzia TM 63 #mg QD [002] 63 Golimumab 63 hepatic metastases 63 invasive candidiasis 63 idarubicin 63 FAMPYRA 63 virologic response 63 double blinded placebo 63 quetiapine Seroquel 63 BRIM3 63 tigecycline 63 Subgroup analyzes 63 Aflibercept 63 Xanafide 63 neratinib 63 Hepatocellular Carcinoma HCC 63 Reverset 63 nucleoside analog 63 tarenflurbil 63 Aplidin 63 AGILECT ® 63 relapsed refractory multiple myeloma 63 interferon beta 1a 63 taxane therapy 63 sargramostim 63 Phenoptin 63 dose dose escalation 63 EURIDIS 63 fosbretabulin 63 nab paclitaxel 63 haloperidol Haldol 63 adefovir 63 Edge STudy 63 EGS# 63 Phase Ib clinical 63 novel VDA molecule 63 PEG IFN 63 CHOP chemotherapy 63 Dacogen injection 63 estramustine 63 EOquin TM 63 abacavir Ziagen 63 Telbivudine 63 standard chemotherapy regimen 63 PROSTVAC TM 63 Tocilizumab 63 TBC# 63 azacitidine 63 Abbott HUMIRA 63 systemic ALCL 63 abatacept 63 alfa 2a 63 AZILECT R 63 HCV infected 63 neoadjuvant 62 pramlintide metreleptin combination 62 Azilect ® 62 AZILECT ® 62 perampanel 62 prior chemotherapy regimens 62 ZOLINZA 62 placebo dexamethasone 62 DEB# 62 Flu Cy 62 sorafenib Nexavar 62 ganetespib 62 Capesaris 62 BR.# 62 Neupro R 62 DermaVir Patch 62 salmeterol fluticasone 62 erlotinib Tarceva ® 62 PD LID 62 Raptiva r 62 Octreolin 62 liver transplant recipients 62 Nexavar sorafenib 62 CUSTOM III 62 dopamine partial agonist 62 RezularTM 62 cMET 62 nucleotide analogue 62 severe gastroparesis 62 calcineurin inhibitor 62 metastatic hormone refractory 62 Gleevec imatinib 62 synthetic retinoid 62 Aptivus ® 62 SPRYCEL ® 62 selective modulator 62 INCB# [001] 62 sunitinib 62 brivaracetam 62 receptor inhibitor 62 TMC# r 62 mg BID 62 novel oral anticoagulant 62 cilostazol 62 Vidaza azacitidine 62 Laquinimod 62 AZT zidovudine Retrovir 62 Cimzia ® 62 macrolide antibiotic 62 Phase IIIb 62 seropositive patients 62 alicaforsen enema 62 CYPHER Stent 62 TEMODAL 62 antiarrhythmic drug 62 nonmetastatic prostate cancer 62 tolvaptan 62 Bezielle 62 ibandronate 62 genotype 1a 62 ß blockers 62 olmesartan 62 mGluR5 NAM 62 HQK 62 ARCOXIA 62 Degarelix 62 relapsed myeloma 62 risperidone Risperdal 62 ACTEMRA 62 undetectable HBV DNA 62 TMC# C# 62 #mg QD [001] 62 Lu AA# 62 bosutinib 62 HGS ETR2 62 VADT 62 Xelox 62 CLL8 62 endothelin receptor antagonists 62 clodronate 62 HER2 positive metastatic breast 62 dalteparin 62 nonrandomized 62 RRMS 62 virologically suppressed 62 untreated AML 62 null responder 62 antiretroviral naïve 62 taxane chemotherapy 62 nonmetastatic 62 hypomethylating agents 62 Phase IIa trial 62 multicenter placebo controlled 62 irinotecan chemotherapy 62 Cladribine Tablets 62 Tanespimycin 62 micafungin 62 Alzhemed TM 62 Gattex 62 metastatic HRPC 62 OvaRex ® MAb 62 definite stent thrombosis 62 androgen suppression 62 psoriatic arthritis PsA 62 EDEMA3 62 Tavocept 62 citalopram hydrobromide 62 ECASS 62 nucleoside analogue 62 paroxysmal AF 62 clomipramine 62 EOquin TM phase 62 Pagoclone 62 ARIMIDEX 62 NATRECOR R 62 CTAP# Capsules 62 visceral metastases 62 pamidronate 62 Subgroup analysis 62 tanespimycin 62 5-FU/LV 62 trabedersen 62 evaluating tivozanib 62 ARIXTRA 62 guanfacine 62 IPX# 62 Crohn disease CD 62 HCV RESPOND 2 62 mildly symptomatic 62 acute leukemias 62 antiepileptics 62 INTELENCE 62 pegylated liposomal doxorubicin 62 USL# 62 EndoTAG TM -1 62 efavirenz EFV 62 smoldering multiple myeloma 62 Telintra 62 thetreatment 62 beta blocker therapy 62 ATACAND 62 sipuleucel T 62 clobazam 62 urocortin 2 62 INCB# [003] 62 Adalimumab 62 multicenter randomized controlled 62 aldosterone antagonist 62 relapsed ovarian cancer 62 TAXUS VI 62 MCyR 62 epoetin beta 62 acyclovir Lauriad R 62 Onrigin 62 relapsed AML 62 colorectal liver metastases 62 venlafaxine Effexor 62 doxorubicin docetaxel 62 Velcade bortezomib 62 COMFORT II 62 caspofungin 62 sustained virologic response 62 mg QD 62 complete cytogenetic response 62 mg/m2 dose 62 superficial bladder cancer 62 demonstrated antitumor activity 62 NP2 Enkephalin 62 Valdoxan 62 rindopepimut 62 anti angiogenic therapy 62 anagrelide 62 safinamide 62 sertraline Zoloft 62 fistulizing Crohn disease 62 anthracycline therapy 62 ziconotide 62 HORIZONS AMI trial 62 enzastaurin 62 goserelin 62 biliary tract cancer 62 Ozarelix 62 Naive Patients 62 entecavir 62 MYLOTARG 62 OncoVEX GM CSF 62 antiepileptic drugs AEDs 61 eszopiclone 61 placebo controlled randomized 61 PXD# 61 Mylotarg 61 citalopram 61 STRIDE PD 61 bronchial thermoplasty 61 treatment naive genotype 61 HIV HCV coinfected 61 flutamide 61 stage IIIB IV 61 OPT CHF 61 DOXIL 61 ACTIVE W 61 virus HCV infection 61 imatinib therapy 61 Phase 1a clinical 61 eculizumab therapy 61 cangrelor 61 KAPIDEX 61 liver histology 61 peginterferon alfa 2b 61 postmenopausal osteoporotic women 61 INC# 61 rufinamide 61 TNF alpha inhibitor 61 QTc prolongation 61 neuropsychiatric symptoms 61 AA Amyloidosis 61 relapsed ALL 61 lenalidomide Revlimid R 61 diabetic neuropathic pain 61 calcineurin inhibitors 61 Hepatotoxicity 61 double blinded randomized 61 NO# [002] 61 evaluating REVLIMID 61 DU #b 61 inhaled iloprost 61 T2DM 61 hematologic toxicity 61 CHAMPION PCI 61 thalidomide Thalomid 61 HBeAg negative patients 61 R# #mg BID 61 mcg albinterferon alfa 2b 61 tolterodine 61 lacosamide 61 dacarbazine 61 CIMZIA R 61 levetiracetam 61 recurrent NSCLC 61 mg administered orally 61 HeFH 61 Angiox R 61 bepotastine besilate nasal spray 61 pentoxifylline 61 ribavirin therapy 61 eosinophilic asthma 61 subcutaneous methylnaltrexone 61 KAPVAY ™ 61 Tyrima 61 atypical Hemolytic Uremic Syndrome 61 LT NS# 61 multicenter randomized 61 hyperphenylalaninemia HPA due 61 nucleoside naive 61 olanzapine LAI 61 chronic ITP patients 61 8mg/kg 61 factor Xa inhibitor 61 timepoint 61 mycophenolate mofetil MMF 61 administered subcutaneously 61 pancreatic neuroendocrine tumors 61 TMS Therapy 61 unresectable stage 61 RAPAFLO R 61 BRAF inhibitor 61 HBeAg + 61 FTY# 61 INTEGRILIN R 61 chronic HBV 61 tamoxifen therapy 61 ara C 61 prospective randomized multicenter 61 everolimus eluting stents 61 Virulizin ® 61 DASISION 61 XELOX 61 Neovascular AMD 61 taxane resistant 61 oral ridaforolimus 61 Ambrisentan 61 subcutaneously administered 61 ruboxistaurin 61 Femara letrozole 61 irbesartan 61 non splenectomized 61 peginterferon alfa 2a 61 GRN# 61 recurrent VTE 61 romidepsin 61 vascular disrupting agent 61 elvucitabine 61 registrational Phase 61 fosamprenavir 61 hepatic fibrosis 61 dosing intervals 61 plus dexamethasone 61 baminercept 61 acetonide FA 61 carboplatin paclitaxel 61 fluticasone furoate 61 ulcerative colitis UC 61 ponatinib 61 AIR2 Trial 61 CA4P 61 nilotinib 61 angiographic outcomes 61 DACH platinum 61 terlipressin 61 paclitaxel eluting stents 61 prospectively defined 61 VFEND 61 bortezomib Velcade 61 metastatic GIST 61 bardoxolone methyl 61 Fludara 61 rALLy clinical trial 61 cariprazine 61 lipid lowering therapy 61 PREZISTA rtv 61 metastatic castration resistant 61 ziprasidone Geodon 61 Genasense ® 61 Fibrillex TM 61 peginterferon 61 imatinib Gleevec ® 61 aldosterone antagonists 61 paliperidone ER 61 preoperative chemotherapy 61 haematologic 61 ritonavir boosted protease inhibitor 61 completely resected 61 retrospective cohort 61 ALT flares 61 CR nPR 61 Allovectin 7 ® 61 paclitaxel cisplatin 61 Mipomersen 61 BARI 2D 61 ospemifene 61 dacarbazine DTIC 61 velaglucerase alfa 61 adjunctive placebo 61 boosted protease inhibitor 61 interferon alfa 2b 61 achieved CCyR 61 relapsed multiple myeloma 61 controlled multicenter 61 APEX PD 61 Phase III randomized 61 cardiac repolarization 61 abacavir lamivudine 61 interferon gamma 1b 61 iniparib 61 metastatic malignant 61 basal bolus regimen 61 humanised monoclonal antibody 61 R roscovitine 61 beta 1a 61 NUVIGIL 61 retinal vein occlusion induced 61 sJIA 61 antidepressant therapy 61 tenofovir emtricitabine 61 Phase III HEAT 61 Cariprazine 61 elevated ALT 61 hypercholesterolemic patients 61 unstable angina UA 61 T1DM 61 velafermin 61 Bendamustine 61 deferiprone 61 IPL# 61 Crizotinib 61 FOLFOX 61 alpha 2a 61 Raptiva R 61 solifenacin 61 LUMINATE 61 dose titration 61 castration resistant prostate cancer 61 GERD migraine headaches 61 dexpramipexole 61 plus prednisone prednisolone 61 desvenlafaxine 61 post herpetic neuralgia PHN 61 lomitapide 61 stage IIIb IV 61 YONDELIS R 61 alefacept 61 HER2 overexpression 61 rimonabant #mg 61 gastrointestinal stromal tumors GIST 61 mg/m2 cohort 61 tafamidis 61 budesonide foam 61 juvenile idiopathic arthritis 61 IFN alfa 61 LY# [003] 61 Daclizumab 61 metastatic bladder 61 ZYBRESTAT fosbretabulin 61 TriRima 61 cabazitaxel 61 DMARD 61 NNRTI resistance 61 null responder HCV 61 ADAGIO study 61 ChronVac C ® 61 multicentre randomized 61 Alequel 61 biologic therapy 61 Glatiramer Acetate 61 mapatumumab 61 anti leukemic 61 rotigotine transdermal patch 61 noninfectious uveitis 61 PRIMO CABG 61 atypical antipsychotic medication 61 enalapril 61 Triapine R 61 Ceflatonin 61 proteasome inhibitor 61 FROVA 61 miglustat 61 acute ischemic stroke 61 Phase #b/#a trial 61 events SAEs 61 neoadjuvant treatment 61 verteporfin 61 methotrexate MTX 61 BOLDER II 61 androgen deprivation 61 vemurafenib 61 LAF# 61 quetiapine 61 ixabepilone 61 ZYVOX 61 6R BH4 61 Cimzia ® certolizumab pegol 61 MNTX 61 basal cell carcinoma BCC 61 briakinumab 61 mg Proellex 61 Nilotinib 61 TEAEs 61 rasagiline 61 comparator arm 61 Pafuramidine 61 concomitant medications 61 dual endothelin receptor antagonist 61 OZURDEX ® 60 alemtuzumab Campath 60 plasma pharmacokinetics 60 efficacy endpoint 60 antiepileptic medications 60 lintuzumab 60 plus MTX 60 metastatic gastric 60 pioglitazone HCl 60 clevidipine 60 PRADAXA 60 tapentadol ER 60 intravenous bisphosphonates 60 protease inhibitors PIs 60 afamelanotide 60 Moli# 60 randomized controlled clinical trials 60 rt PA 60 pancreatic NET 60 QTc 60 #mg dose [002] 60 postoperative chemotherapy 60 XmAb# 60 Serious adverse reactions 60 BEXXAR 60 PROSTVAC ® 60 INVEGA 60 multicenter Phase II 60 trastuzumab DM1 60 anti arrhythmic drug 60 zolmitriptan 60 intravenous RSD# 60 REVIVE Diabetes 60 partial remissions 60 receptor blocker 60 Cimzia R 60 infliximab Remicade 60 ARCALYST ® 60 Irinotecan 60 sustained virological response 60 recurrent malignant glioma 60 XIENCE V PROMUS Stent 60 CRLX# 60 Free Survival PFS 60 CoFactor 60 rheumatoid arthritis psoriatic arthritis 60 esomeprazole 60 Tacrolimus 60 randomized Phase IIb 60 ZD# [001] 60 cortical stimulation 60 thorough QT 60 ascending dose 60 Vectibix monotherapy 60 PegIntron 60 Symadex 60 LPV r 60 GOUT 60 interferon therapy 60 Campath alemtuzumab 60 rosuvastatin #mg 60 FOLFIRI 60 TAXUS Stent 60 perioperatively 60 metastatic malignant melanoma 60 LymphoStat B belimumab 60 ARB telmisartan 60 events AEs 60 Phase IIa trials 60 LUX Lung 60 CCR5 inhibitor 60 ARIKACE 60 Aptivus 60 decompensated liver disease 60 Pharmacokinetics PK 60 Dacogen decitabine 60 pharmacokinetics PK 60 RAPTIVA 60 Zavesca ® 60 CINTREDEKIN BESUDOTOX 60 p# inhibitor 60 hepatitis C genotype 60 levodopa therapy 60 metastatic CRC 60 morphometric vertebral fractures 60 3TC lamivudine Epivir 60 mesalazine 60 infliximab 60 refractory gout 60 phase 2a 60 idursulfase 60 thrombocytopenic 60 standard chemotherapy regimens 60 GLYX 60 ELOXATIN 60 anti TNF 60 Mitoxantrone 60 PEG SN# 60 PEGINTRON TM 60 methylnaltrexone 60 carotid artery stenting 60 MAS XR 60 NeuroStar TMS Therapy 60 AEG# 60 CTEPH 60 radiation sensitizer 60 hereditary deficiency 60 Rilonacept 60 AMEVIVE 60 EQUIP OB 60 CAELYX 60 midstage clinical 60 RISPERDAL ® 60 LIALDA 60 fingolimod 60 ELND# 60 INSPIRE Trial Phase III 60 CYP#D# inhibitor 60 achieved sustained virological 60 ONGLYZA saxagliptin 60 hepatorenal syndrome 60 IBS C 60 chromium picolinate supplementation 60 Archexin 60 fibromyalgia syndrome 60 urate lowering therapy 60 Gleevec resistant 60 ribavirin RBV 60 paliperidone palmitate 60 Phase 2a clinical 60 systemically administered 60 Inhaled nitric oxide 60 NOXAFIL Oral Suspension 60 docetaxel Taxotere ® 60 Noxafil 60 nadolol 60 Pertuzumab 60 pharmacokinetic PK study 60 severe exacerbations 60 ramelteon 60 follicular lymphomas 60 Platinol ® cisplatin 60 DPNP 60 proliferative diabetic retinopathy 60 monotherapy 60 registrational trial 60 latent tuberculosis infection 60 Dapagliflozin 60 weekly intravenous infusions 60 Sprycel dasatinib 60 Cytoxan 60 virologic 60 rituximab Rituxan 60 FluCAM arm 60 denufosol 60 Randomized Phase 60 warfarin therapy 60 FASLODEX 60 symptomatic paroxysmal AF 60 randomized controlled Phase 60 TELCYTA 60 gemifloxacin 60 PHX# 60 refractory AML 60 Pharmacokinetic studies 60 mTOR inhibitors 60 schizophrenia CIAS 60 Iloperidone 60 Akt inhibitor 60 KRN# 60 Aryplase 60 darunavir r 60 palonosetron 60 indolent NHL 60 direct thrombin inhibitors 60 corticosteroid therapy 60 nonsmall cell lung cancer 60 dexamethasone Decadron 60 lanthanum carbonate 60 dasatinib 60 VAPRISOL 60 HBV infections 60 Carfilzomib 60 T2 lesions 60 XL# SAR# 60 azilsartan medoxomil 60 relapsed SCLC 60 paroxetine Paxil 60 PREZISTA ritonavir 60 dasatinib Sprycel 60 BMS # 60 Eculizumab 60 idraparinux 60 thiazolidinediones TZDs 60 eltrombopag